Open AccessCYTOCHROME P450 (CYP2C9) ACTIVENESS, EVALUATED VIA LOSARTAN TEST, AS PREDICTION MARKER FOR THE WARFARIN TREATMENT DOSAGE CHOICE IN PATIENTS WITH DELAYED OUTCOMES AFTER HEART VALVES REPLACEMENT
Author(s) -
С. М. Арсланбекова,
Д. А. Сычев,
К. Б. Мирзаев,
Р. Е. Казаков,
В. В. Смирнов,
Н. М. Магомедова,
Е.З. Голухова
Publication year - 2015
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2015-10-70-74
Subject(s) - losartan , medicine , cyp2c9 , warfarin , urine , cardiology , heart failure , urology , pharmacology , atrial fibrillation , angiotensin ii , cytochrome p450 , blood pressure , metabolism